This Article Full Text Full Text (PDF) Data Supplement Data Supplement All Versions of this Article: 119/8/1135    most recent CIRCULATIONAHA.108.810721v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGillicuddy, F. C. Articles by Reilly, M. P. Search for Related Content PubMed PubMed Citation Articles by McGillicuddy, F. C. Articles by Reilly, M. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL Related Collections Pathophysiology Risk Factors Cell biology/structural biology Lipid and lipoprotein metabolism

(Circulation. 2009;119:1135-1145.)
© 2009 American Heart Association, Inc.

Vascular Medicine

Inflammation Impairs Reverse Cholesterol Transport In Vivo

Fiona C. McGillicuddy, PhD; Margarita de la Llera Moya, PhD; Christine C. Hinkle, MS; Michelle R. Joshi, BSc; Elise H. Chiquoine, BSc; Jeffrey T. Billheimer, PhD; George H. Rothblat, PhD; Muredach P. Reilly, MBBCh

From the Cardiovascular Institute and Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia (F.C.M., C.C.H., E.H.C., J.T.B., M.P.R.); and Gastrointestinal and Nutrition Division, Children’s Hospital of Philadelphia, Philadelphia, Pa (M.d.l.L.M., G.H.R.).

Correspondence to Muredach P. Reilly, Cardiovascular Institute, University of Pennsylvania Medical Center, 609 BRB 2/3, 421 Curie Blvd, Philadelphia, PA 19104-6160. E-mail muredach{at}spirit.gcrc.upenn.edu

Received July 29, 2008; accepted December 17, 2008.

Background— Inflammation is proposed to impair reverse cholesterol transport (RCT), a major atheroprotective function of high-density lipoprotein (HDL). The present study presents the first integrated functional evidence that inflammation retards numerous components of RCT.

Methods and Results— We used subacute endotoxemia in the rodent macrophage-to-feces RCT model to assess the effects of inflammation on RCT in vivo and performed proof of concept experimental endotoxemia studies in humans. Endotoxemia (3 mg/kg SC) reduced ³H-cholesterol movement from macrophage to plasma and ³H-cholesterol associated with HDL fractions. At 48 hours, bile and fecal counts were markedly reduced consistent with downregulation of hepatic expression of ABCG5, ABCG8, and ABCB11 biliary transporters. Low-dose lipopolysaccharide (0.3 mg/kg SC) also reduced bile and fecal counts, as well as expression of biliary transporters, but in the absence of effects on plasma or liver counts. In vitro, lipopolysaccharide impaired ³H-cholesterol efflux from human macrophages to apolipoprotein A-I and serum coincident with reduced expression of the cholesterol transporter ABCA1. During human (3 ng/kg; n=20) and murine endotoxemia (3 mg/kg SC), ex vivo macrophage cholesterol efflux to acute phase HDL was attenuated.

Conclusions— We provide the first in vivo evidence that inflammation impairs RCT at multiple steps in the RCT pathway, particularly cholesterol flux through liver to bile and feces. Attenuation of RCT and HDL efflux function, independent of HDL cholesterol levels, may contribute to atherosclerosis in chronic inflammatory states including obesity, metabolic syndrome, and type 2 diabetes.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				A. Undurti, Y. Huang, J. A. Lupica, J. D. Smith, J. A. DiDonato, and S. L. Hazen Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle J. Biol. Chem., November 6, 2009; 284(45): 30825 - 30835. [Abstract] [Full Text] [PDF]